In vitro dissolution of generic immediate-release solid oral dosage forms containing BCS class I drugs: comparative assessment of metronidazole, zidovudine, and amoxicillin versus relevant comparator pharmaceutical products in South Africa and India.
Biowaivers are recommended for immediate-release solid oral dosage forms using dissolution testing as a surrogate for in vivo bioequivalence studies. Several guidance are currently available (the World Health Organization (WHO), the US FDA, and the EMEA) where the conditions are described. In this study, definitions, criteria, and methodologies according to the WHO have been applied. The dissolution performances of immediate-release metronidazole, zidovudine, and amoxicillin products purchased in South African and Indian markets were compared to the relevant comparator pharmaceutical product (CPP)/reference product. The dissolution performances were studied using US Pharmacopeia (USP) apparatus 2 (paddle) set at 75 rpm in each of three dissolution media (pH1.2, 4.5, and 6.8). Concentrations of metronidazole, zidovudine, and amoxicillin in each dissolution media were determined by HPLC. Of the 11 metronidazole products tested, only 8 could be considered as very rapidly dissolving products as defined by the WHO, whereas 2 of those products could be considered as rapidly dissolving products but did not comply with the f 2 acceptance criteria in pH 6.8. All 11 zidovudine products were very rapidly dissolving, whereas in the case of the 14 amoxicillin products tested, none of those products met any of the WHO criteria. This study indicates that not all generic products containing the same biopharmaceutics classification system (BCS) I drug and in similar strength and dosage form are necessarily in vitro equivalent. Hence, there is a need for ongoing market surveillance to determine whether marketed generic products containing BCS I drugs meet the release requirements to confirm their in vitro bioequivalence to the respective reference product.
Basic Science Research Center, KLE University, Belgaum, Karnataka, 590010, India.
Nallagundla H S
NH
Reddy
Srinivas
S
Patnala
Raimar
R
Löbenberg
Isadore
I
Kanfer
D000658:Amoxicillin / Q000737:chemistry*; D000900:Anti-Bacterial Agents / Q000737:chemistry*; D019380:Anti-HIV Agents / Q000737:chemistry*; D000994:Antitrichomonal Agents / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D065546:Drug Liberation; D016568:Drugs, Generic; D007194:India; D008795:Metronidazole / Q000737:chemistry*; D012995:Solubility; D013019:South Africa; D015215:Zidovudine / Q000737:chemistry*
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000994:Antitrichomonal Agents; D004304:Dosage Forms; D016568:Drugs, Generic; D008795:Metronidazole; D015215:Zidovudine; D000658:Amoxicillin